Matthew J. Gardella

Mergers & Acquisitions

  • Syncona Ltd. (LSE: SYNC) in its acquisition of Freeline Therapeutics (Nasdaq: FRLN)
  • Standard BioTools (Nasdaq: LAB) in its stock-for-stock merger with SomaLogic (Nasdaq: SLGC)
  • F-star Therapeutics (Nasdaq:  FSTX) in its $161 million sale to invoX Pharma, a subsidiary of Sino Biopharma Limited (HKEX 1177 HK), with voluntary CFIUS and NSIA filings and full foreign investment regulatory review and clearance. This transaction is the first successfully completed acquisition by a Chinese entity of a U.S. publicly traded biotech company in over a decade
  • Syncona Ltd. (LSE: SYNC) in its acquisition of Applied Genetics Technologies (Nasdaq: AGTC) for $23.3 million in cash, plus up to $50 million payable pursuant to contingent value rights
  • Viela Bio (Nasdaq:VIE) in its $3.05 billion sale to Horizon Therapeutics (Nasdaq: HZNP), ranked in Fierce Biotech’s “The Top 10 Biopharma M&A Deals in 2021”
  • QIAGEN N.V. (NYSE: QGEN; Frankfurt: QIA) in its $12.5 billion proposed sale to Thermo Fisher Scientific, Inc. (NYSE: TMO)
  • Netsmart Technologies in multiple acquisitions
  • Synlogic, Inc. in its merger with Mirna Therapeutics, Inc. (Nasdaq: MIRN)
  • Molecular Templates, Inc. in its merger with Threshold Pharmaceuticals, Inc. (Nasdaq: THLD)
  • Synta Pharmaceuticals (Nasdaq: SNTA) in its merger with Madrigal Pharmaceuticals
  • Atlantic Tele-Network (Nasdaq: ATNI) in its $145 million acquisition of Innovative Group
  • Essilor International SA in its $270 million acquisition of Costa Inc. (Nasdaq: ATX)
  • FGX International in its acquisition of Stylemark
  • ASSA ABLOY AB in its $80 million acquisition of LaserCard Corporation (Nasdaq: LCRD)
  • ABRY Partners, a private equity firm, in its $1.3 billion acquisition of RCN Corporation (Nasdaq: RCNI)
  • Cequent Pharmaceuticals in its sale to Marina Biotech, Inc. (Nasdaq: MRNAD), formerly known as MDRNA, Inc.
  • Dynasil Corporation of America (Nasdaq: DYSL) in its acquisition of Hilger Crystal Limited, a U.K. subsidiary of Newport Corp. (Nasdaq: NEWP)
  • Management team of Netsmart Technologies, Inc. in connection with the acquisition of Netsmart by private equity firm, Genstar Capital, including terms of management’s “roll-over” and co-investment arrangements and related employment and compensation arrangements
  • Takeda Pharmaceutical Company Limited (TSE:4502) in its $8.8 billion acquisition of Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM), one of the largest foreign acquisitions by a Japanese company, the largest by a Japanese company in the pharmaceutical industry and IDD magazine‘s “Healthcare Deal of the Year” in 2008
  • Lane, Berry & Co. International LLC in its sale to Raymond James Financial, Inc.
  • XIUS – bcgi in its sale of substantially all of its interests in its Israeli subsidiary, Puresight Technologies Limited
  • Boston Communications Group, Inc. (Nasdaq: BCGI) in its $65 million merger with Megasoft Limited
  • Helix Technology Corporation (Nasdaq: HELX) in its agreement to merge with Brooks Automation in a $450 million stock swap

Securities Offerings

  • Freeline Therapeutics in its $26.1 million follow-on offering (investor’s counsel)
  • Rezolute, Inc. in its $41 million PIPE in connection with a Nasdaq uplisting (lead investor’s counsel)
  • Spero Therapeutics, Inc. in its IPO and multiple follow-on offerings 
  • Molecular Templates, Inc. in multiple follow-on offerings
  • Adaptimmune Therapeutics plc in its $100 million follow-on offering (investors' counsel)
  • Synlogic, Inc. in multiple follow-on offerings 
  • WAVE Life Sciences Ltd. in its $102 million IPO
  • Achillion Pharmaceuticals, Inc. in its $141.4 million follow-on offering (underwriters' counsel)
  • TECO Energy in its $280.5 million public offering of common stock
  • Stemline Therapeutics, Inc. in its $30 million IPO
  • Recapitalization transaction of SofTech, Inc.
  • Atlantic Tele-Network in its $68 million public offering of common stock
Case Study

Mintz Guides Spero to Another Follow-On Public Offering

Mintz represented Spero Therapeutics, a clinical-stage biopharmaceutical company developing treatments for drug-resistant bacterial infections, in a September 2020 underwritten public offering that netted $80 million in gross proceeds before the deduction of underwriting discounts and commissions.
Case Study

Fueling Synlogic’s Growing Pipeline

Mintz represented Synlogic in an $80 million financing from Ginkgo Bioworks and the parties' related collaboration to expand development of Synlogic’s Synthetic Biotic medicines. Mintz previously helped Synlogic raise over $200 million in capital, plus another $40 million through a reverse merger.
Case Study

Mintz Advises Spero Therapeutics on Collaboration

Mintz advised biopharma company Spero Therapeutics on an agreement with Everest Medicines regarding the development and commercialization of a product to treat multidrug-resistant bacterial infections and option to license another.
Case Study

Mintz Guides Spero to Follow-On Offering

In July 2018 Mintz represented Spero Therapeutics, a multi-asset clinical stage biopharmaceutical company, in its underwritten public offering. The offering included 3,780,000 shares of its common stock and 2,220 shares of its non-voting Series A Convertible Preferred Stock, with the gross proceeds to Spero being $75M prior to the deduction of any underwriting discounts and commissions.
Case Study

Representing Synlogic, Inc. from Inception to IPO

Mintz’s work for synthetic biotic company Synlogic Inc. has included raising over $100 million in three VC financing rounds. Mintz attorneys also helped Synlogic form a multiyear global R&D collaboration with AbbVie and raise more than $40 million in an IPO via a reverse merger with Mirna Therapeutics.